


SMS PHARMACEUTICALS LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Standalone Un Audited Financial Results for the Quarter Ended 30th June, 2018

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended		Year ended	
		30.06.2018 (Unaudited)	31.03.2018 (Refer Note 4) (Audited)		30.06.2017 (Unaudited)
1	Revenue From Operations	12,510.66	10,123.91	13,261.79	46,486.33
2	Other Income	36.14	110.62	41.85	238.79
3	Total Revenue	12,546.80	10,234.53	13,303.64	46,725.12
4	Expenses				
	(a) Cost of materials consumed	8,339.98	4,805.58	7,676.85	29,432.23
	(b) Changes in inventories	(302.38)	373.42	1,539.02	(442.31)
	(c) Central Excise Duty	-	-	261.58	218.81
	(d) Manufacturing Expenses	1,032.25	829.72	800.88	3,450.40
	(e) Employee Benefits Expense	859.82	974.89	715.21	3,280.34
	(f) Finance costs	301.87	367.93	351.41	1,547.96
	(g) Depreciation and amortisation expense	475.34	500.63	493.56	1,989.98
	(h) Other expenses	210.44	458.54	236.95	1,212.89
5	Total Expenses - (a to h)	10,917.32	8,310.71	12,075.46	40,690.30
	Profit before Exceptional and Extraordinary Items and Tax (3-4)	1,629.48	1,923.82	1,228.18	6,034.82
6	Exceptional items	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	1,629.48	1,923.82	1,228.18	6,034.82
8	Extraordinary Items	-	-	-	-
9	Profit before Tax (7-8)	1,629.48	1,923.82	1,228.18	6,034.82
10	Tax Expenses				
	(1) Current Tax	350.00	384.50	265.00	1,276.15
	(2) Deferred Tax	268.05	568.50	40.08	713.24
		618.05	953.00	305.08	1,989.39
11	Net Profit / (Loss) for the Period (9-10)	1,011.43	970.82	923.10	4,045.43
12	Other Comprehensive Income (OCI):				
	(A) Items that will not be reclassified				
	Remeasurements of post-employment benefit obligations	(1.58)	41.71	(15.40)	6.31
13	Total Other Comprehensive Income before related Tax	(1.58)	41.71	(15.40)	6.31
14	Income Tax on OCI	(0.55)	14.45	(5.33)	2.20
15	Other Comprehensive Income after tax for the Year (13-14)	(1.03)	27.26	(10.07)	4.11
16	Total comprehensive Income for the period (11+14)	1,010.40	998.08	913.03	4,049.54



17	Earning Per Equity Share (of Re.1/- each) (not annualised) (a) Basic (b) Diluted	1.19 1.19	1.15 1.15	1.09 1.09	4.78 4.78
18	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52
19	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				29,264.04

Notes:

- The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 28th July, 2018 and have been approved by the Board of Directors at its meeting held on 28th July, 2018.
- Results for the quarter ended 30th June, 2018 were subjected to 'Limited Review' by the Auditors.
- The company has opted to publish standalone unaudited financial results and would be consolidating and presenting its consolidated financial statements as at and for the year ended 31.03.2019.
- The figures for the quarter ended 31.03.2018 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of year ended 31.03.2018
- These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed Under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- Revenue from operations for the quarter ended 30th June, 2018 is shown net of Goods and Services Tax (GST). However, net sales for the corresponding quarter is shown inclusive of excise duty. Year ended 31st March, 2018 includes excise duty upto 30th June, 2017. The following additional information is being provided to facilitate better understanding.

Particulars	Quarter Ended		Year ended
	30.06.2018	30.06.2017	
Revenue from Operations	13,598.14	11,047.61	13,261.79
GST Recovered	1,087.48	923.70	-
Excise Duty on Sale	-	-	255.17
Revenue from Operations excluding GST/Excise Duty	12,510.66	10,123.91	13,006.62
			46,231.16

- Figures of previous period have been regrouped / rearranged wherever necessary.



For SMS Pharmaceuticals Limited

Ramesh Babu Potluri
Chairman and Managing Director

Place: Hyderabad
Date : 28-07-2018



Limited Review Report

To
The Board of Directors
SMS PHARMACEUTICALS LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS PHARMACEUTICALS LIMITED ("the Company"), for the quarter ended 30th June 2018 ("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 28-07-2018

For Suryanarayana & Suresh.,
Chartered Accountants
Reg. No.006631S

V Nagendra Rao
Partner
M. No. 227679

